← Leaderboards
Jesse Hong-Sae Erasmus
Access To Advanced Health Institute
$5,357,788
Attributed
$5,592,106
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,592,106 · 5
By mechanism
U19$4,361,524 · 1
R43$597,388 · 2
R21$468,636 · 1
F32$164,558 · 1
Top collaborators
- Albert J. Auguste2 shared
Others in their field
Other Emerging Leaders on “Antigens”
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$42,191,190
- Bala Raja · Luminostics, Inc.$28,624,460
- Hanjoon Ryu$28,519,898
- Thomas Denny · Duke University$22,999,550
- Jay Evans · University Of Montana$22,565,626
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
AntigensVaccinesInfectionTechnologyVirusVaccine DevelopmentRna VaccineImmune ResponseResponseImmunogenicityDoseCovid-19 PandemicSafetyRepliconAntibodiesDesignPathogenImmunityVaccine PlatformVaccine EfficacyViralFutureImmuneT Cell Response
Grant awards (10)
Research Project 3: Rapid-Response Roadmap for RNA vaccines$2,270,214
U19 · FY2025 · AI · contact PI
Research Project 3: Rapid-Response Roadmap for RNA vaccines$2,091,310
U19 · FY2024 · AI · contact PI
Pre-clinical evaluation of alpha-Cache; a novel RNA vaccine for an emerging orthobunyavirus$206,342
R21 · FY2024 · AI
Pre-clinical evaluation of alpha-Cache; a novel RNA vaccine for an emerging orthobunyavirus$262,294
R21 · FY2023 · AI
Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets$192,720
R43 · FY2023 · AI · contact PI
Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets$104,692
R43 · FY2022 · AI · contact PI
Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis$299,976
R43 · FY2021 · AI · contact PI
Development of a novel replicating viral RNA vaccine platform$44,294
F32 · FY2020 · AI · contact PI
Development of a novel replicating viral RNA vaccine platform$61,610
F32 · FY2019 · AI · contact PI
Development of a novel replicating viral RNA vaccine platform$58,654
F32 · FY2018 · AI · contact PI